IRONWOOD PHARMACEUTICALS, INC. Research and Development Expense
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Research and Development Expense of $22.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $22.42M, a 4.07% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $21.94M, a 20.02% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $21.86M, a 13.89% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $22.47M, a 24.67% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $95.14M, a 14.62% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $111.42M.
- IRONWOOD PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $44.27M, a 37.13% decline from fiscal 2021.
- IRONWOOD PHARMACEUTICALS, INC. research and development expense for fiscal 2021 was $70.41M, a 20.05% decline from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.42M 10-Q · filed 2026-08-06 | $44.36M 10-Q · filed 2026-08-06 | $66.22M derived: sum of 3 quarters · filed 2026-08-06 | $88.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $21.94M 10-Q · filed 2026-05-07 | $43.80M derived: sum of 2 quarters · filed 2026-05-07 | $66.27M derived: sum of 3 quarters · filed 2026-05-07 | $89.64M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $21.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $44.33M derived: sum of 2 quarters · filed 2026-02-26 | $67.70M derived: sum of 3 quarters · filed 2026-08-06 | $95.14M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $22.47M 10-Q · filed 2025-11-10 | $45.84M derived: sum of 2 quarters · filed 2026-08-06 | $73.27M 10-Q · filed 2025-11-10 | $98.66M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $23.37M 10-Q · filed 2026-08-06 | $50.80M 10-Q · filed 2026-08-06 | $76.20M derived: sum of 3 quarters · filed 2026-08-06 | $106.02M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $27.43M 10-Q · filed 2026-05-07 | $52.82M derived: sum of 2 quarters · filed 2026-05-07 | $82.65M derived: sum of 3 quarters · filed 2026-05-07 | $113.04M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $25.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $55.22M derived: sum of 2 quarters · filed 2026-02-26 | $85.61M derived: sum of 3 quarters · filed 2026-02-26 | $111.42M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $29.83M 10-Q · filed 2025-11-10 | $60.22M derived: sum of 2 quarters · filed 2025-11-10 | $86.03M 10-Q · filed 2025-11-10 | $1.11B derived: sum of 4 quarters · filed 2026-04-28 | ||||
| 2024-06-30 | $30.39M 10-Q · filed 2025-08-11 | $56.20M 10-Q · filed 2025-08-11 | $1.08B derived: sum of 3 quarters · filed 2026-04-28 | $1.11B derived: sum of 4 quarters · filed 2026-04-28 | ||||
| 2024-03-31 | $25.82M 10-Q · filed 2025-05-12 | $1.05B derived: sum of 2 quarters · filed 2026-04-28 | $1.08B derived: sum of 3 quarters · filed 2026-04-28 | $1.11B derived: sum of 4 quarters · filed 2026-04-28 | ||||
| 2023-12-31 | $1.02B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | $1.05B derived: sum of 2 quarters · filed 2026-04-28 | $1.09B derived: sum of 3 quarters · filed 2026-04-28 | $1.10B DEF 14A · filed 2026-04-28 | $116.08M 10-K · filed 2024-02-16 | |||
| 2023-09-30 | $32.98M 10-Q · filed 2024-11-07 | $67.56M derived: sum of 2 quarters · filed 2024-11-07 | $80.41M 10-Q · filed 2024-11-07 | $90.86M derived: sum of 4 quarters · filed 2025-03-31 | ||||
| 2023-06-30 | $34.58M 10-Q · filed 2024-08-08 | $47.42M 10-Q · filed 2024-08-08 | $57.87M derived: sum of 3 quarters · filed 2025-03-31 | $69.42M derived: sum of 4 quarters · filed 2025-03-31 | ||||
| 2023-03-31 | $12.85M 10-Q · filed 2024-05-09 | $23.29M derived: sum of 2 quarters · filed 2025-03-31 | $34.84M derived: sum of 3 quarters · filed 2025-03-31 | $46.29M derived: sum of 4 quarters · filed 2025-03-31 | ||||
| 2022-12-31 | $10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $21.99M derived: sum of 2 quarters · filed 2025-03-31 | $33.44M derived: sum of 3 quarters · filed 2025-03-31 | $44.27M 10-K · filed 2025-03-31 | ||||
| 2022-09-30 | $11.54M 10-Q · filed 2023-11-09 | $23.00M derived: sum of 2 quarters · filed 2023-11-09 | $33.82M 10-Q · filed 2023-11-09 | $65.67M derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-06-30 | $11.45M 10-Q · filed 2023-08-09 | $22.27M 10-Q · filed 2023-08-09 | $54.13M derived: sum of 3 quarters · filed 2024-02-16 | $65.03M derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-03-31 | $10.82M 10-Q · filed 2023-05-04 | $42.67M derived: sum of 2 quarters · filed 2024-02-16 | $53.58M derived: sum of 3 quarters · filed 2024-02-16 | $65.74M derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2021-12-31 | $31.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $42.76M derived: sum of 2 quarters · filed 2024-02-16 | $54.92M derived: sum of 3 quarters · filed 2024-02-16 | $70.41M 10-K · filed 2024-02-16 | ||||
| 2021-09-30 | $10.91M 10-Q · filed 2022-11-03 | $23.07M derived: sum of 2 quarters · filed 2022-11-03 | $38.55M 10-Q · filed 2022-11-03 | $54.82M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-06-30 | $12.16M 10-Q · filed 2022-08-04 | $27.65M 10-Q · filed 2022-08-04 | $43.91M derived: sum of 3 quarters · filed 2023-02-16 | $65.61M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-03-31 | $15.48M 10-Q · filed 2022-05-05 | $31.75M derived: sum of 2 quarters · filed 2023-02-16 | $53.44M derived: sum of 3 quarters · filed 2023-02-16 | $75.52M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2020-12-31 | $16.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $37.96M derived: sum of 2 quarters · filed 2023-02-16 | $60.03M derived: sum of 3 quarters · filed 2023-02-16 | $88.06M 10-K · filed 2023-02-16 | ||||
| 2020-09-30 | $21.69M 10-Q · filed 2021-11-04 | $43.77M derived: sum of 2 quarters · filed 2021-11-04 | $71.80M 10-Q · filed 2021-11-04 | $98.33M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | $22.08M 10-Q · filed 2021-08-05 | $50.10M 10-Q · filed 2021-08-05 | $76.64M derived: sum of 3 quarters · filed 2022-02-18 | $104.19M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | $28.03M 10-Q · filed 2021-05-06 | $54.56M derived: sum of 2 quarters · filed 2022-02-18 | $82.11M derived: sum of 3 quarters · filed 2022-02-18 | $110.87M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | $26.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $54.09M derived: sum of 2 quarters · filed 2022-02-18 | $82.85M derived: sum of 3 quarters · filed 2022-02-18 | $115.04M 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | $27.55M 10-Q · filed 2020-11-05 | $56.31M derived: sum of 2 quarters · filed 2020-11-05 | $88.51M 10-Q · filed 2020-11-05 | $116.75M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-06-30 | $28.76M 10-Q · filed 2020-08-06 | $60.96M 10-Q · filed 2020-08-06 | $89.19M derived: sum of 3 quarters · filed 2021-02-17 | $118.35M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-03-31 | $32.20M 10-Q · filed 2020-05-06 | $53.99M 10-Q · filed 2019-05-02 | $60.44M derived: sum of 2 quarters · filed 2021-02-17 | $89.59M derived: sum of 3 quarters · filed 2021-02-17 | $112.78M derived: sum of 4 quarters · filed 2021-02-17 | |||
| 2018-12-31 | $28.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $57.40M derived: sum of 2 quarters · filed 2021-02-17 | $80.58M derived: sum of 3 quarters · filed 2021-02-17 | $101.06M 10-K · filed 2021-02-17 | $166.50M 10-K · filed 2019-02-25 | |||
| 2018-09-30 | $29.16M 10-Q · filed 2019-10-31 | $46.79M 10-Q · filed 2018-11-06 | $52.34M derived: sum of 2 quarters · filed 2019-10-31 | $72.82M 10-Q · filed 2019-10-31 | $122.23M 10-Q · filed 2018-11-06 | $68.88M derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-06-30 | $23.19M 10-Q · filed 2019-07-30 | $38.93M 10-Q · filed 2018-08-06 | $43.66M 10-Q · filed 2019-07-30 | $75.44M 10-Q · filed 2018-08-06 | $39.73M derived: sum of 3 quarters · filed 2020-02-13 | $76.79M derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-03-31 | $36.51M 10-Q · filed 2019-05-02 | $16.54M derived: sum of 2 quarters · filed 2020-02-13 | $53.60M derived: sum of 3 quarters · filed 2020-02-13 | $90.95M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | -$19.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $17.10M derived: sum of 2 quarters · filed 2020-02-13 | $54.44M derived: sum of 3 quarters · filed 2020-02-13 | $88.14M 10-K · filed 2020-02-13 | $148.23M 10-K · filed 2018-02-22 | |||
| 2017-09-30 | $37.06M 10-Q · filed 2018-11-06 | $74.41M derived: sum of 2 quarters · filed 2018-11-06 | $108.11M 10-Q · filed 2018-11-06 | $146.55M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2017-06-30 | $37.34M 10-Q · filed 2018-08-06 | $71.05M 10-Q · filed 2018-08-06 | $109.49M derived: sum of 3 quarters · filed 2019-02-25 | $147.01M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2017-03-31 | $33.70M 10-Q · filed 2018-05-04 | $72.14M derived: sum of 2 quarters · filed 2019-02-25 | $109.67M derived: sum of 3 quarters · filed 2019-02-25 | $141.35M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2016-12-31 | $38.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $75.97M derived: sum of 2 quarters · filed 2019-02-25 | $107.65M derived: sum of 3 quarters · filed 2019-02-25 | $139.49M 10-K · filed 2019-02-25 | ||||
| 2016-09-30 | $37.53M 10-Q · filed 2017-11-02 | $69.21M derived: sum of 2 quarters · filed 2017-11-02 | $101.05M 10-Q · filed 2017-11-02 | $128.68M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-06-30 | $31.68M 10-Q · filed 2017-08-03 | $63.52M 10-Q · filed 2017-08-03 | $91.15M derived: sum of 3 quarters · filed 2018-02-22 | $116.98M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-03-31 | $31.84M 10-Q · filed 2017-05-08 | $59.47M derived: sum of 2 quarters · filed 2018-02-22 | $85.30M derived: sum of 3 quarters · filed 2018-02-22 | $113.95M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2015-12-31 | $27.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $53.46M derived: sum of 2 quarters · filed 2018-02-22 | $82.11M derived: sum of 3 quarters · filed 2018-02-22 | $108.75M 10-K · filed 2018-02-22 | ||||
| 2015-09-30 | $25.83M 10-Q · filed 2016-11-07 | $54.48M derived: sum of 2 quarters · filed 2016-11-07 | $81.12M 10-Q · filed 2016-11-07 | $108.60M derived: sum of 4 quarters · filed 2017-02-22 | ||||
| 2015-06-30 | $28.65M 10-Q · filed 2016-08-08 | $55.29M 10-Q · filed 2016-08-08 | $82.77M derived: sum of 3 quarters · filed 2017-02-22 | $107.89M derived: sum of 4 quarters · filed 2017-02-22 | ||||
| 2015-03-31 | $26.64M 10-Q · filed 2016-05-10 | $54.12M derived: sum of 2 quarters · filed 2017-02-22 | $79.25M derived: sum of 3 quarters · filed 2017-02-22 | $101.39M derived: sum of 4 quarters · filed 2017-02-22 | ||||
| 2014-12-31 | $27.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $52.60M derived: sum of 2 quarters · filed 2017-02-22 | $74.75M derived: sum of 3 quarters · filed 2017-02-22 | $101.89M 10-K · filed 2017-02-22 | ||||
| 2014-09-30 | $25.12M 10-Q · filed 2015-11-05 | $47.26M derived: sum of 2 quarters · filed 2015-11-05 | $74.41M 10-Q · filed 2015-11-05 | $96.92M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | $22.14M 10-Q · filed 2015-08-07 | $49.29M 10-Q · filed 2015-08-07 | $71.80M derived: sum of 3 quarters · filed 2016-02-19 | $94.82M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | $27.14M 10-Q · filed 2015-05-06 | $49.66M derived: sum of 2 quarters · filed 2016-02-19 | $72.68M derived: sum of 3 quarters · filed 2016-02-19 | $96.77M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2013-12-31 | $22.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $45.53M derived: sum of 2 quarters · filed 2016-02-19 | $69.63M derived: sum of 3 quarters · filed 2016-02-19 | $102.38M 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | $23.02M 10-Q · filed 2014-11-05 | $47.11M derived: sum of 2 quarters · filed 2014-11-05 | $79.86M 10-Q · filed 2014-11-05 | $108.14M derived: sum of 4 quarters · filed 2015-02-18 | ||||
| 2013-06-30 | $24.09M 10-Q · filed 2014-08-05 | $56.85M 10-Q · filed 2014-08-05 | $85.12M derived: sum of 3 quarters · filed 2015-02-18 | $108.57M derived: sum of 4 quarters · filed 2015-02-18 | ||||
| 2013-03-31 | $32.75M 10-Q · filed 2014-04-29 | $61.03M derived: sum of 2 quarters · filed 2015-02-18 | $84.48M derived: sum of 3 quarters · filed 2015-02-18 | $116.72M derived: sum of 4 quarters · filed 2015-02-18 | ||||
| 2012-12-31 | $28.27M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | $51.73M derived: sum of 2 quarters · filed 2015-02-18 | $83.96M derived: sum of 3 quarters · filed 2015-02-18 | $113.47M 10-K · filed 2015-02-18 | ||||
| 2012-09-30 | $23.45M 10-Q · filed 2013-10-28 | $55.69M derived: sum of 2 quarters · filed 2013-10-28 | $85.20M 10-Q · filed 2013-10-28 | $109.42M derived: sum of 4 quarters · filed 2014-02-07 | ||||
| 2012-06-30 | $32.24M 10-Q · filed 2013-08-08 | $61.75M 10-Q · filed 2013-08-08 | $85.97M derived: sum of 3 quarters · filed 2014-02-07 | $108.88M derived: sum of 4 quarters · filed 2014-02-07 | ||||
| 2012-03-31 | $29.51M 10-Q · filed 2013-04-23 | $53.73M derived: sum of 2 quarters · filed 2014-02-07 | $76.64M derived: sum of 3 quarters · filed 2014-02-07 | $96.05M derived: sum of 4 quarters · filed 2014-02-07 | ||||
| 2011-12-31 | $24.22M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-07 | $47.13M derived: sum of 2 quarters · filed 2014-02-07 | $66.54M derived: sum of 3 quarters · filed 2014-02-07 | $86.09M 10-K · filed 2014-02-07 | ||||
| 2011-09-30 | $22.91M 10-Q · filed 2012-11-06 | $42.31M derived: sum of 2 quarters · filed 2012-11-06 | $61.87M 10-Q · filed 2012-11-06 | $83.14M derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2011-06-30 | $19.41M 10-Q · filed 2012-08-07 | $38.96M 10-Q · filed 2012-08-07 | $60.23M derived: sum of 3 quarters · filed 2013-02-21 | $78.97M derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2011-03-31 | $19.55M 10-Q · filed 2012-05-10 | $40.82M derived: sum of 2 quarters · filed 2013-02-21 | $59.56M derived: sum of 3 quarters · filed 2013-02-21 | $79.46M derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2010-12-31 | $21.27M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $40.01M derived: sum of 2 quarters · filed 2013-02-21 | $59.91M derived: sum of 3 quarters · filed 2013-02-21 | $77.45M 10-K · filed 2013-02-21 | ||||
| 2010-09-30 | $18.74M 10-Q · filed 2011-11-09 | $38.64M derived: sum of 2 quarters · filed 2011-11-09 | $56.19M 10-Q · filed 2011-11-09 | |||||
| 2010-06-30 | $19.90M 10-Q · filed 2011-08-12 | $37.45M 10-Q · filed 2011-08-12 | ||||||
| 2009-12-31 | $76.10M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |